Search Results
Apr 21, 2026, 12:45 ET Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
for the treatment of relapsed or refractory NSCLC harboring EGFR exon20ins. WU-KONG28 is a phase 3 randomized pivotal study comparing sunvozertinib vs. chemo doublet in previously untreated NSCLC patients with EGFR exon20ins mutation. Earlier, Dizal announced that the study had met its primary endpoint
More news about: Dizal Pharmaceutical
Apr 21, 2026, 12:34 ET Q1 2026 revenue of 27.6 m€: another consecutive quarter of sequential growth (+8%)
Q1 2026vs. Q1 2025ChangeQ1 2026vs. Q4 2025
More news about: Ekinops
Apr 21, 2026, 12:00 ET New EaseUS Research Reveals 72% of SD Card Data Loss Can Be Recovered Successfully
lower share of about 5% to 6%. The remaining brands together account for about 12.7% of the distribution.The Tool Divide: Hardcore Control vs. One-Click SimplicityReddit experts champion deep control tools for hexadecimal-level operations, while average users prioritize determinism,
More news about: EaseUS Software
Apr 21, 2026, 10:26 ET Grads Should Look for Hospitality Jobs in the Midwest, Not NY and LA - OysterLink
The Midwest vs. The CoastsMid-sized cities are currently posting double or triple the entry-level opportunities found in NYC or LA:
More news about: OysterLink
Apr 21, 2026, 10:15 ET IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
Number: LBA9503Date and Time: June 1, 2026, 8-11AM CDT, Oral Abstract Session, Melanoma/Skin CancersTitle: Darovasertib Plus Crizotinib vs Investigator's Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 trialPresenter:
More news about: IDEAYA Biosciences, Inc.
Apr 21, 2026, 10:10 ET THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY PRESENTS LANDMARK SYMPOSIUM CHAMPIONING EVIDENCE-BASED DERMATOLOGY AND COLLABORATION
Medicine, presented by Dr. Courtney M. Johnson, 2021 Dermatology Research Award RecipientRisk of Psychiatric Comorbidities in Scarring vs Non-Scarring Alopecia: A Retrospective Cohort Study, an oral abstract presented by Nicole J. Baker, BSPresentations by Early Career Innovations
More news about: Skin of Color Society
Apr 21, 2026, 10:01 ET Wires & Cables Market to Reach USD 635 Billion by 2036 Electrification, EVs, and AI Infrastructure Reshape Demand | Market Decipher
annual copper demand growth from automotive aloneGreen-transition sectors outpace traditional apps: grid expansion +19%, renewables +7%, vs. legacy industrial +0.5%Aurubis AG (2025): commissioned a U.S. cable scrap recycling plant — circular copper is becoming a competitive
More news about: Market Decipher
Apr 21, 2026, 09:30 ET New 5WPR Study Finds That Israeli Tech Companies Generate $7.3 billion in Florida's Economy
USIBA 2025Wage premium vs. FL average12% higher
More news about: 5W Public Relations
Apr 21, 2026, 09:30 ET ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
seller Culper Research's report, "ADMA Biologics Inc. (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3.5% Real Growth in 2025 vs. +20% Reported."
More news about: Hagens Berman Sobol Shapiro LLP
Apr 21, 2026, 09:05 ET Dyson unveils the Supersonic™ Travel: 32% Smaller. 25% Lighter. Still mighty.
1Vs the original Dyson Supersonic hair dryer based on body weight287% agree their hair feels healthy, based on a Consumer Test of 98 participants vs participants' existing travel dryer. Conducted in January 2026392%
More news about: Dyson
Apr 21, 2026, 09:01 ET Bluevine Study Reveals 3 in 4 Small Business Owners Say It's Worth It, But More Than Half Hit a Cash Flow Crisis First
New Bluevine report reveals a significant Expectation vs. Reality gap: 3 in 4 SBOs say it's worth it, but 27% of owners report higher-than-expected burnout. JERSEY CITY, N.J., April 21, 2026 /PRNewswire/ --
More news about: Bluevine
Apr 21, 2026, 09:00 ET West Coast Community Bancorp Announces Earnings and Dividend for the First Quarter of 2026
Change % vs.March
More news about: West Coast Community Bancorp
Apr 21, 2026, 08:59 ET America's AI Report Card: 45 of 50 States Fail to Protect Student Thinking From AI
of The Effort Crisis, and a contributor to ABC's 20/20 and BBC Radio.The study scores each state across seven weighted criteria: Teach vs. Ban AI, Critical Thinking, Student Effort and Cognitive Development, AI Literacy, Teacher Training, Assessment Integrity, and Equity. Struggle is how
More news about: Kevin J. Roberts
Apr 21, 2026, 08:43 ET Pritchard Industries Accelerates Fleet Modernization as Part of Decarbonization Strategy
results:Estimated annual CO₂ reduction: ~188 metric tonsEmissions reduction per vehicle: ~64% decrease vs. legacy fleetOperational impact: Lower Scope 1 emissions across service delivery"This is a clear example of how operational
More news about: Pritchard Industries
Apr 21, 2026, 08:30 ET IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026
More news about: IceCure Medical
Apr 21, 2026, 08:00 ET REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia
patency outcomes of 70% for MOTIV vs. 48% for balloon angioplasty, representing a 22% absolute improvementEarly clinical benefit observed at 6 months, with limb salvage and primary patency achieved in 81% of MOTIV patients vs. 62% for balloon angioplastyPrimary
More news about: REVA Medical, LLC
Apr 21, 2026, 08:00 ET REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia
patency outcomes of 70% for MOTIV vs. 48% for balloon angioplasty, representing a 22% absolute improvementEarly clinical benefit observed at 6 months, with limb salvage and primary patency achieved in 81% of MOTIV patients vs. 62% for balloon angioplastyPrimary
More news about: REVA Medical, LLC
Apr 21, 2026, 07:44 ET Bitmine Immersion Technologies (BMNR) kondigt aan dat de ETH-bezittingen zijn gestegen tot 4,976 miljoen tokens, met totale crypto- en contante bezittingen van 12,9 miljard dollar.
Bitmine (NYSE: BMNR) is een Bitcoin-miner met activiteiten in de VS. Het bedrijf zet zijn overtollige kapitaal in om het toonaangevende Ethereum-treasurybedrijf ter wereld te worden, waarbij het een innovatieve strategie
More news about: Bitmine Immersion Technologies, Inc.
Apr 21, 2026, 07:15 ET Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease
https://www.researchgate.net/publication/260118801_Nitinol_Self-Expanding_Stents_vs_Balloon_Angioplasty_for_Very_Long_Femoropopliteal_Lesions
More news about: Efemoral Medical
Apr 21, 2026, 07:00 ET Greenvit Debuts ARONVIT® for Gut Health and Microbiota at Vitafoods Europe
sourced from the special Nero-Eggert variety of aronia berries, a variety recognized for its high yield of polyphenols.Polyphenols vs. fibers"For many consumers, especially those with sensitive digestion, high doses of fiber can cause bloating, cramping, and discomfort," explains
More news about: Greenvit
Apr 21, 2026, 06:00 ET Danaher Reports First Quarter 2026 Results
% Change Three-Month Period Ended March 27, 2026 vs. Comparable 2025 Period
More news about: Danaher Corporation
Apr 21, 2026, 03:31 ET ACG METALS LIMITED: Q1 2026 Operations and Capital Structure Update
Q1 2026vs Q1 2025
More news about: ACG METALS LIMITED
Apr 20, 2026, 19:35 ET Hozpitality Group Announces Los Angeles Hospitality Leadership Forum 2026, Featuring Top Industry Leaders and Timely Panel Discussions
feature two high-impact panel discussions addressing some of the most pressing challenges and opportunities in the hospitality industry:Profit vs Pressure: Can Hotels in Los Angeles Still Win in 2026?Margins are tightening—discover how top hotels are staying profitable in a high-cost
More news about: Hozpitality Group
Apr 20, 2026, 17:35 ET In HelloNation, Swimming Expert Woody Alpern of Atlanta Compares Swim School vs Community Swim Lessons for Kids
ATLANTA, April 20, 2026 /PRNewswire/ -- When choosing the right program, how can parents compare swim school vs community swim lessons? A
More news about: HelloNation
Apr 20, 2026, 16:05 ET Washington Trust Reports First Quarter 2026 Results
Mar 31, 2026 vs. Dec 31, 2025Mar 31, 2026 vs. Mar 31, 2025
More news about: Washington Trust Bancorp, Inc.